2.Treatment for traumatic optic neuropathy with mouse nerve growth factor:a meta-analysis
International Eye Science 2015;(4):633-635
AIM:To evaluate the efficacy of treating traumatic optic neuropathy( TON) with mouse nerve growth factor.
METHODS: We searched the Cochrane Library, Pubmed, Medline, CNKI, Wanfang database and VIP to collect randomized controlled trials ( RCTs ) of using mouse nerve growth factor for TON. The quality of the included trials was assessed and poor-qualified trials were eliminated before the meta - analysis was conducted.
RESULTS:Seven RCTs with a total of 399 eyes included were retrieved, and OR=3. 78 with a 95%CI of [ 2. 35, 6.06], the difference was significant (P<0. 01).
CONCLUSION:The existing evidence supports that the prognosis of TON is better when mouse nerve growth factor are adopted in treatment, but there is still a need for well-planned, large-scale and multicenter RCTs to verify it.
3.Research progress of the association between PAX6 gene and retinal diseases
International Eye Science 2014;(9):1606-1607
PAX6 gene plays an important role in embryological development, and the mutation of this gene may result incongenital aniridia, retinoblastoma, macula hypoplasia, Peters' anomaly and so on. A brief introduction of the background PAX6 gene, and the association between PAX6 and retinal diseases were summarized in this review.
4.Progress of targeted therapy related to K-ras mutation.
Chinese Journal of Pathology 2012;41(1):59-61
Antineoplastic Agents
;
therapeutic use
;
Colorectal Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
Genes, ras
;
genetics
;
Humans
;
Lung Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
Molecular Targeted Therapy
;
methods
;
Mutation
;
Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
Pancreatic Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
Proto-Oncogene Proteins
;
genetics
;
metabolism
;
Proto-Oncogene Proteins p21(ras)
;
Receptor, Epidermal Growth Factor
;
drug effects
;
metabolism
;
Signal Transduction
;
ras Proteins
;
genetics
;
metabolism
5.Research updates on vesicle-associated membrane protein-associated protein 33.
Chinese Journal of Pathology 2011;40(11):790-792
Amyotrophic Lateral Sclerosis
;
genetics
;
Animals
;
Biological Transport, Active
;
Bipolar Disorder
;
genetics
;
Glucose Transporter Type 4
;
metabolism
;
Hepacivirus
;
physiology
;
Humans
;
Neoplasm Metastasis
;
Neoplasms
;
metabolism
;
Point Mutation
;
Polymorphism, Single Nucleotide
;
R-SNARE Proteins
;
metabolism
;
Tissue Distribution
;
Transport Vesicles
;
physiology
;
Vesicular Transport Proteins
;
chemistry
;
genetics
;
metabolism
;
physiology
;
Virus Replication
6.Common clinical types and management of secondary glaucoma after ocular trauma
Jing, REN ; Jing-Wen, LIU ; Bo, QIN
International Eye Science 2016;16(6):1071-1075
?Ocular trauma related glaucoma is one of secondary glaucoma, which can lead to serious visual loss. According to the complex clinical findings and pathogenesis of ocular trauma related glaucoma, we divide traumatic secondary glaucoma into hyphema related glaucoma, angle recession related, lens injury related, adhesion and proliferation related. The treatment of secondary traumatic glaucoma with ocular trauma were different, specific treatment measures should be given according to the specific case to protect visual function.
9.Quantitative study of corticospinal tract in patients with multiple sclerosis using diffusion tensor tractography
Kuncheng LI ; Chunshui YU ; Wen QIN ; Zhuoxia LIU
Chinese Journal of Radiology 2000;0(11):-
0.05). The average FA of the corticospinal tracts (0.472?0.037) of RRMS group was significantly lower than that of normal control group (0.497?0.028) (P0.05). The average FA of the corticospinal tracts correlated with EDSS (r=-0.193, P0.05). Conclusion The average FA of the corticospinal tracts of RRMS patients is significantly abnormal and this index may be suitable in evaluating the functional status of the cerebral type of RRMS patients.
10.Clinical safety and efficacy of shortened period of clopidogrel treatment after BuMA stent ;implantation in elderly coronary heart disease patients over 75 years old
Jieyun LIU ; Lei QIN ; Yaoxin WANG ; Wen YANG ; Zhenjun WANG
Chinese Journal of Interventional Cardiology 2016;24(1):37-39
Objective To evaluate the clinical efficacy and safety of domestic BuMA biodegradable drug eluting coronary stent in elderly coronary heart disease patients over 75 years old with shortened duration of clopidogrel treatment. Methods 100 elderly patients who received coronary angiography and PCI were included, and they were randomly divided into the observation group ( n=50, received oral clopidogrel for 9 months) and the control group (n=50, received oral clopidogrel for 12 months). The occurance of angina pectoris, AMI, bleeding events and the results of control angiography were compared between the two groups after 12 months of follow-up. Results All the 100 patients were followed up in 12 months after discharge. 4 patients ( 8. 0%) in the observation group and 3 patients ( 6. 0%) in the control group had recurrent angina. Control coronary angiography 12 months later showed no restenosis in the stents. There was no significant difference between the two groups in the recurrence of angina pectoris and coronary stent restenonsis. No acute myocardial infarction,cliniacl bleeding events and late stent thrombosis occurred in the two groups. Conclusions The application of the domestic BuMA biodegradable drug eluting stent for the treatment of coronary heart disease patients over 75 years old is safe and effective with shortened duration of clopidogel treatment.